Search Results - "Hinojosa del Val, Joaquín"

  • Showing 1 - 19 results of 19
Refine Results
  1. 1

    COVID-19 and the digestive system: protection and management during the SARS-CoV-2 pandemic by Crespo, Javier, Iglesias-García, Julio, Hinojosa Del Val, Joaquin E, García García, Federico, Gil de Miguel, Ángel, Fernández Carrillo, Carlos, Ampuero, Javier, Pérez-Cuadrado Martínez, Enrique

    “…The purpose of this rapid review is to provide an update on the impact of SARS-CoV-2 infection on Gastroenterology and Hepatology departments, our patients,…”
    Get full text
    Journal Article
  2. 2

    Update of the SEPD position statement on the use of biosimilars for inflammatory bowel disease by Argüelles Arias, Federico, Hinojosa Del Val, Joaquín, Vera Mendoza, Isabel

    “…In 2013, the European Medicines Agency (EMA) approved the biosimilar infliximab (CT-P13) for the full range of indications of the originator product, based on…”
    Get full text
    Journal Article
  3. 3

    Old-age inflammatory bowel disease onset:A different problem by del Val, Joaquin Hinojosa

    Published in World journal of gastroenterology : WJG (14-06-2011)
    “…Inflammatory bowel disease (IBD) in patients aged 60 accounts for 10%-15% of cases of the disease. Diganostic methods are the same as for other age groups…”
    Get full text
    Journal Article
  4. 4

    Clinical settings with tofacitinib in ulcerative colitis by Taxonera, Carlos, Carpio López, Daniel, Cabez Manas, Ana, Hinojosa Del Val, Joaquin Ernesto

    “…There are aspects of Janus kinase (JAK) inhibitors, specifically tofacitinib, that distinguish them from other drugs used in the treatment of ulcerative…”
    Get full text
    Journal Article
  5. 5

    Questions and answers about the management of Crohn's disease and ulcerative colitis with vedolizumab by Hinojosa Del Val, Joaquín, Barreiro-de Acosta, Manuel

    Published in Gastroenterología y hepatología (01-12-2019)
    “…Vedolizumab is an anti-integrin monoclonal antibody indicated for the treatment of patients with moderately to severely active Crohn's disease and ulcerative…”
    Get more information
    Journal Article
  6. 6
  7. 7

    Use of teduglutide for short bowel syndrome and Crohn's disease in a patient treated with ustekinumab and vedolizumab dual biologic therapy by Martí Romero, Lidia, Peño Muñoz, Laura, Martínez Escapa, Vanesa, Hinojosa Del Val, Joaquín

    “…Surgery in Crohn's disease may be the cause of short bowel syndrome that may lead to kidney dysfunction. Dual biologic therapy is rarely needed to control…”
    Get full text
    Journal Article
  8. 8

    Author´s answer to: "Effect of adacolumn® in ulcerative colitis with COVID-19" by Hinojosa Del Val, Joaquín, Crespo, Javier, Pérez-Cuadrado Martínez, Enrique

    “…We have read with interest the article published by Pérez et al., we really appreciate their interesting comments and would like to qualify some points. With…”
    Get full text
    Journal Article
  9. 9
  10. 10

    Questions and answers about the management of Crohn’s disease and ulcerative colitis with vedolizumab by Hinojosa del Val, Joaquín, Barreiro-de Acosta, Manuel

    “…Vedolizumab is an anti-integrin monoclonal antibody indicated for the treatment of patients with moderately to severely active Crohn’s disease and ulcerative…”
    Get full text
    Journal Article
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19